Clinical trial
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
NCT00595920
Study timeline
Study start (unknown)2007-11-01Date precision: month
Registry last updated2016-03-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosis, Relapsing-Remittingunresolved
Clinically Isolated Syndromeunresolved
Interventions
TovaxinBIOLOGICAL
Sponsors & collaborators
Opexa Therapeutics, Inc.lead sponsor
Mapped research locations
PhoenixArizona, United States2HoustonTexas, United States1PhiladelphiaPennsylvania, United States1San AntonioTexas, United States1ColumbusOhio, United States1PortlandOregon, United States1CharlotteNorth Carolina, United States1LexingtonKentucky, United States1RaleighNorth Carolina, United States1AlbanyNew York, United States1DaytonOhio, United States1Colorado SpringsColorado, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00595920 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.